Makiko Kobayashi

Chuo, 1038426, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Inhibition of bone erosion, determined by high-resolution peripheral quantitative computed tomography (HR-pQCT), in rheumatoid arthritis patients receiving a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) plus denosumab vs csDMARD therapy alone: an open-label, randomized, parallel-group study.

Inhibition of bone erosion, determined by high-resolution peripheral quantitative computed tomography (HR-pQCT), in rheumatoid arthritis patients receiving a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) plus denosumab vs csDMARD therapy alone: an open-label, randomized, parallel-group study.

Journal: Arthritis research & therapy

Published: June 29, 2022

Correction to: Impact of denosumab discontinuation on changes in bone mineral density and bone erosion in rheumatoid arthritis patients.

Correction to: Impact of denosumab discontinuation on changes in bone mineral density and bone erosion in rheumatoid arthritis patients.

Journal: Modern rheumatology

Published: December 01, 2021

Fracture risk associated with glucocorticoid-induced osteoporosis in Japan.

Fracture risk associated with glucocorticoid-induced osteoporosis in Japan.

Journal: Journal of bone and mineral metabolism

Published: October 13, 2021

Epidemiology of glucocorticoid-induced osteoporosis and management of associated fracture risk in Japan.

Epidemiology of glucocorticoid-induced osteoporosis and management of associated fracture risk in Japan.

Journal: Journal of bone and mineral metabolism

Published: March 31, 2021

Impact of denosumab discontinuation on changes in bone mineral density and bone erosion in rheumatoid arthritis patients.

Impact of denosumab discontinuation on changes in bone mineral density and bone erosion in rheumatoid arthritis patients.

Journal: Modern rheumatology

Published: March 12, 2021

Efficacy of denosumab co-administered with vitamin D and Ca by baseline vitamin D status.

Efficacy of denosumab co-administered with vitamin D and Ca by baseline vitamin D status.

Journal: Journal of bone and mineral metabolism

Published: March 24, 2020

Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies.

Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies.

Journal: Modern rheumatology

Published: December 13, 2019

Comparative study of the inhibitory effect on bone erosion progression with denosumab treatment and conventional treatment in rheumatoid arthritis patients: study protocol for an open-label randomized controlled trial by HR-pQCT.

Comparative study of the inhibitory effect on bone erosion progression with denosumab treatment and conventional treatment in rheumatoid arthritis patients: study protocol for an open-label randomized controlled trial by HR-pQCT.

Journal: Trials

Published: April 01, 2019

Showing 1-8 of 8

Last Updated: 09/26/2026